Observational studyMedicine2026
Cumulative exposure to the remnant cholesterol inflammation index and incident diabetes mellitus in middle-aged and elderly Chinese adults: A nationwide cohort study from CHARLS.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The remnant cholesterol inflammation index (RCII) is a novel biomarker integrating remnant cholesterol and high-sensitivity C-reactive protein. Whether long-term exposure to RCII is associated with diabetes mellitus (DM) remains unclear. We examined the association between cumulative RCII (cumRCII) exposure and incident DM risk in the China Health and Retirement Longitudinal Study. We included 5817 participants with DM at baseline from the China Health and Retirement Longitudinal Study 2011 to 2015. Logistic regression models and restricted cubic splines were used to examine the relationship between cumRCII and DM risk, adjusting for potential confounding factors. Subgroup analysis was used to examine potential effect modification, and sensitivity analysis was used to test the robustness of the primary findings. A total of 786 new-onset DM cases occurred. Participants in the highest quartile of cumRCII levels had a higher DM risk than those in the lowest quartile (odds ratio = 2.47; 95% confidence interval = 1.95-3.12; Ptrend < .001). Each 1-SD increment in cumRCII was associated with a 25% increased risk (odds ratio = 1.25; 95% confidence interval = 1.18-1.33). Restricted cubic spline analysis indicated a positive and nonlinear association between cumRCII and DM (Pfor overall < .001; Pfor nonlinearity < .001). Subgroup analysis revealed consistent associations between cumRCII and DM risk (all Pfor interaction > .05). E-value analysis suggested robustness to unmeasured confounding. Elevated long-term cumRCII is significantly associated with higher DM risk in middle-aged and elderly Chinese adults, suggesting that cumRCII may serve as a potential biomarker for identifying individuals at higher metabolic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.